...
首页> 外文期刊>Physiological genomics >Transcriptional profiling reveals ductus arteriosus-specific genes that regulate vascular tone
【24h】

Transcriptional profiling reveals ductus arteriosus-specific genes that regulate vascular tone

机译:转录分析揭示动脉导管特异性基因调节血管张力

获取原文
获取原文并翻译 | 示例

摘要

Shelton EL, Ector G, Galindo CL, Hooper CW, Brown N, Wilkerson I, Pfaltzgraff ER, Paria BC, Cotton RB, Stoller JZ, Reese J. Transcriptional profiling reveals ductus arteriosus-specific genes that regulate vascular tone. Physiol Genomics 46: 457-466, 2014. First published May 1, 2014; doi:10.1152/physiolgenomics.00171.2013.-Failure of the ductus arteriosus (DA) to close at birth can lead to serious complications. Conversely, certain profound congenital cardiac malformations require the DA to be patent until corrective surgery can be performed. In each instance, clinicians have a very limited repertoire of therapeutic options at their disposal - indomethacin or ibuprofen to close a patent DA (PDA) and prostaglandin E1 to maintain patency of the DA. Neither treatment is specific to the DA and both may have deleterious off-target effects. Therefore, more therapeutic options specifically targeted to the DA should be considered. We hypothesized the DA possesses a unique genetic signature that would set it apart from other vessels. A microarray was used to compare the genetic profiles of the murine DA and ascending aorta (AO). Over 4,000 genes were differentially expressed between these vessels including a subset of ion channel-related genes. Specifically, the alpha and beta subunits of large-conductance calcium-activated potassium (BKCa) channels are enriched in the DA. Gain- and loss-of-function studies showed inhibition of BKCa channels caused the DA to constrict, while activation caused DA relaxation even in the presence of O_2. This study identifies subsets of genes that are enriched in the DA that may be used to develop DA-specific drugs. Ion channels that regulate DA tone, including BKCa channels, are promising targets. Specifically, BKCa channel agonists like NS1619 maintain DA patency even in the presence of O_2 and may be clinically useful.
机译:Shelton EL,Ector G,Galindo CL,Hooper CW,Brown N,Wilkerson I,Pfaltzgraff ER,Paria BC,Cotton RB,Stoller JZ,Reese J. Physiol Genomics 46:457-466,2014年。2014年5月1日首次发布; doi:10.1152 / physiolgenomics.00171.2013.-动脉导管破裂(DA)出生时关闭可能导致严重的并发症。相反,在进行矫正手术之前,某些严重的先天性心脏畸形需要DA获得专利。在每种情况下,临床医生只能使用非常有限的治疗选择-吲哚美辛或布洛芬来关闭专利DA(PDA),前列腺素E1来维持DA的通畅。两种治疗方法都不是DA特有的,并且都可能具有有害的脱靶作用。因此,应考虑更多针对DA的治疗选择。我们假设DA拥有独特的遗传特征,可使其与其他血管区分开。使用微阵列比较鼠DA和升主动脉(AO)的遗传概况。这些血管之间有超过4,000个基因差异表达,其中包括离子通道相关基因的一个子集。具体来说,大电导钙激活钾(BKCa)通道的α和β亚基富含DA。功能获得和功能丧失研究表明,即使存在O_2,对BKCa通道的抑制也会导致DA收缩,而激活则会导致DA松弛。这项研究确定了富含DA的基因子集,可用于开发DA特异性药物。调节DA音调的离子通道(包括BKCa通道)是有前途的目标。具体而言,即使在O_2存在的情况下,BKCa通道激动剂(如NS1619)仍可保持DA的通畅,在临床上可能有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号